What is Monod Bio?
Monod Bio operates at the intersection of synthetic biology and diagnostic engineering. The company specializes in the creation of sophisticated biosensors capable of detecting a wide array of biological markers, including complex viral proteins and environmental toxins. By focusing on high-sensitivity molecular recognition, Monod Bio addresses critical gaps in current diagnostic infrastructure, offering potential applications that range from rapid clinical testing to environmental monitoring. Its position in the Seattle biotech ecosystem allows it to tap into a rich talent pool and collaborative research environment, further cementing its role as a key player in the next generation of molecular diagnostics.
How much funding has Monod Bio raised?
Monod Bio has raised a total of $31M across 2 funding rounds:
Angel/Seed
$6M
Angel/Seed
$25M
Angel/Seed (2021): $6M, investors not publicly disclosed
Angel/Seed (2022): $25M led by Matrix Capital Advisors, Global Health Investment Corporation, Cercano Management, Boom Capital Ventures, and Washington Research Foundation
Key Investors in Monod Bio
Matrix Capital Advisors
Matrix Capital Advisors provides holistic wealth management and customized investment solutions tailored to each client's unique goals, needs and values.
Washington Research Foundation
Washington Research Foundation supports research and scholarship in Washington state, with a focus on life sciences and enabling technologies, acting as a key catalyst for regional startup growth.
Global Health Investment Corporation
An investment firm focused on financing global health innovations and technologies that address critical medical challenges in underserved markets.
What's next for Monod Bio?
With the successful closure of this major strategic investment, Monod Bio is expected to prioritize the scaling of its core technology platform. The roadmap likely includes intensified R&D efforts to broaden the detection spectrum of its biosensors and the initiation of pilot programs to validate the technology in real-world clinical settings. As the company matures, the focus will shift toward commercialization strategies and potential partnerships with larger healthcare entities. The backing from institutional investors suggests a long-term commitment to building a sustainable enterprise capable of disrupting traditional diagnostic methodologies through superior sensitivity and speed.
See full Monod Bio company page
